Roundup Of Q311's Pharmaceutical Share Price Performances

Since BMI launched its Global Company Strategy reports in July 2011, stock markets worldwide have experienced a period of extreme uncertainty and share price weakness in light of the European sovereign debt crisis and doubts about global macroeconomic growth in the coming years. This is the primary reason that BMI's Pharma 20 Index fell by 9.2% from July 1 to September 30. During this period of selling off, BMI noticed that there was little difference between the loss in share price of pharmaceutical stocks and that of the main global share price indices. However, since late August the Pharma 20

To read the full article, please choose one of the following options: